Recommendations from the ACG Task Force

In December of 2008, the ACG IBS Task Force issued an evidence-based position statement and systematic review on the management of IBS. The tables below summarize the grading criteria and findings.1

The ACG grading recommendations are described as follows:

  • 1A: Strong recommendation with high-quality evidence
  • 1B: Strong recommendation with moderate-quality evidence
  • 1C: Strong recommendation with low-quality or very low-quality evidence
  • 2A: Weak recommendation with high-quality evidence
  • 2B: Weak recommendation with moderate-quality evidence
  • 2C: Weak recommendation with low-quality or very low-quality evidence

LOTRONEX® is the only FDA-approved Grade 1-B medication for the treatment of severe IBS-D.1

Reference:

  1. 1. Brandt LJ, Chey WD, Foxx-Orenstein AE, et al; American College of Gastroenterology Task Force on Irritable Bowel Syndrome.
        An evidence-based systematic review on the management of irritable bowel syndrome. Am J Gastroenterol.
        2009;104(suppl 1):S1-S35.

Click here for complete prescribing information, including Boxed Warning, for LOTRONEX®.